ARTICLES

Filter  
Active filters 0
Remove
  

Refine your searches by:

Collections
Biology
Medicine / Sub specialtie
Public health
Pure sciences
Research
Chemistry
Medicine / Pharmacology
Veterinary
Architecture and Urbanism
Environment
all records (72)

Languages
English
Spanish
Portuguese
German

Countries
Indonesia
USA
Brazil
Ukraine
Italy
Romania
India
Iran
Poland
Macedonia
all records (72)

Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
all records (24)

Filter  
 
1.583.039  Articles
1 of 158.305 pages  |  10  records  |  more records»
Evidences are accumulating that CD4+ T cells can physiologically mediate antigen specific target cell lysis. By circumventing major histocompatibility complex (MHC)-restrictions through an engineered chimeric antigen receptor (CAR), CD4+ T cells lyse defi... see more

Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being ... see more

Chimeric Antigen Receptor (CAR) T-cells are T-cells with recombinant receptors targeted to tumor antigens. CAR-T cell therapy has emerged as a mode of immunotherapy and is now being extensively explored in hematologic cancer. In contrast, CAR-T cell use i... see more

T cells expressing chimeric antigen receptors (CARs) recognizing CD19 epitopes have produced remarkable anti-tumor effects in patients with B-cell malignancies. However, cancer cells lacking recognized epitopes can emerge, leading to relapse and death. Th... see more

In cancer therapy, currently used approaches include surgery, radio- and chemotherapy and various combinations of these. Immunotherapy is emerging as the ‘fourth pillar’ of cancer therapy. Science Magazine declared cancer immunotherapy as a ‘breakthrough ... see more

CD47 is a glycoprotein of the immunoglobulin superfamily that is often overexpressed in different types of hematological and solid cancer tumors and plays important role in blocking phagocytosis, increased tumor survival, metastasis and angiogenesis. In t... see more

T cell non-Hodgkin lymphoma (T-NHL) is a rare and heterogeneous group of neoplasms of the lymphoid system. With the exception of a few relatively indolent entities, T-NHL is typically aggressive, treatment resistant, and associated with poor prognosis. Re... see more

Programmed cell death protein-1 (PD-1) is an immune checkpoint receptor that induces and maintains tolerance of T cells, invariant natural killer T (iNKT) cells, and natural killer (NK) cells, among other lymphocytes. Immune checkpoint inhibition by PD-1 ... see more

Chimeric antigen receptor (CAR) T cell therapy still faces the challenge of immunosuppression when treating solid tumors. TGF-ß is one of the critical factors in the tumor microenvironment to help tumors escape surveillance by the immune system. Here we t... see more

1 of 158.305 pages  |  10  records  |  more records»